Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sanofi, Sanofi en nog eens Sanofi

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts
Pagina: «« 1 ... 35 36 37 38 39 40 »» | Laatste | Omlaag ↓
  2. [verwijderd] 15 november 2010 12:36
    Een lange neus naar Viesbacher?

    Dit had er met Crucell moeten gebeuren, maar klooster Leiden wil dat natuulijk niet.

    Beleggersonbelangen.

    Takeda Pharmaceutical In Talks To Buy Genzyme For $18.5 Bln
    -Report

    Last update: 11/14/2010 8:13:44 PM

    DOW JONES NEWSWIRES
    Takeda Pharmaceutical Co. (4502.TO) is in talks to buy U.S.-based biotechnology company Genzyme Corp. (GENZ) for more than $18.5 billion, or Y1.525 trillion, U.K. newspaper The Mail reported Sunday citing a source close to the matter.

    Genzyme, which makes treatments for multiple sclerosis and rare genetic diseases, is looking for a higher offer after France's Sanofi-Aventis S.A. (SAN.FR) launched a hostile bid last month at $69 per share, the newspaper said.

    Genzyme, which has 11,000 staff worldwide, has approached several large drugs firms in recent weeks to act as a white knight, including GlaxoSmithKline PLC (GSK.LN), Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE).

    According to the newspaper, the source said Takeda could pay $82 a share for the business, adding: "The firm is actively looking to expand in the U.S. and would have no problem financing the deal."

    -Tokyo Bureau, Dow Jones Newswires; +81-3-6269-2770 (END)

    Dow Jones Newswires

    November 14, 2010 20:13 ET (01:13 GMT)
  3. maxen 15 november 2010 22:40
    quote:

    Dirk R. Wijnen schreef:

    Een lange neus naar Viesbacher?

    Dit had er met Crucell moeten gebeuren, maar klooster Leiden wil dat natuulijk niet.
    ...
    Takeda Pharmaceutical Co. (4502.TO) is in talks to buy U.S.-based biotechnology company Genzyme Corp. (GENZ) for more than $18.5 billion, or Y1.525 trillion, U.K. newspaper The Mail reported Sunday citing a source close to the matter.

    Genzyme...is looking for a higher offer after France's Sanofi-Aventis S.A. (SAN.FR) launched a hostile bid last month at $69 per share, the newspaper said.

    Genzyme ... has approached several large drugs firms in recent weeks to act as a white knight, including GlaxoSmithKline PLC (GSK.LN), Eli Lilly & Co. (LLY) and Pfizer Inc. (PFE).
    ...
    No White Knight for Genzyme

    Genzyme (GENZ) Chief Henri Termeer looks desperate.

    He insists that his company is worth $89 a share -- much more than Sanofi-Aventis' (SNY) unsolicited bid of $69 a share. But to date, there is no sign a serious counter bid is coming.

    The latest development: Takeda Pharmaceutical reportedly took a look at struggling Genzyme. One media source even quoted a possible $82 a share bid, putting the deal price north of $20 billion. While Takeda aggressively pursues partnerships and is making smaller acquisitions, there’s nothing indicating the Japanese drug maker has an appetite for a transaction anywhere near this big.
    ...
    It’s painfully clear now that Termeer has little choice but to sit down and negotiate with Sanofi CEO Christopher Viehbacher, who refuses to budge from his $18.5 billion offer. Perhaps Cambridge, Massachusetts-based Genzyme can squeeze a few more dollars a share out of Sanofi. But the reality is that if Genzyme manages to ward off Sanofi but doesn’t find another buyer (a scenario that’s increasingly likely), the stock is going to plunge.

    For Sanofi, the price is right. Viehbacher says he’s not going to bid against himself and, at this point, he doesn’t have enough information about Genzyme’s business to up his offer. Termeer has been reluctant to open the kimono to the French drug exec.
    ...
    Sanofi’s offer expires December 10. At that point, the company can walk away, up its bid for Genzyme or extend the offer. At this point, Sanofi appears to have the upper hand. A white knight emerging at this point seems unlikely.
    tinyurl.com/27487yg
  4. [verwijderd] 18 november 2010 12:17
    Sekisui Chemical: To Buy Genzyme Corp Diagnostic Operations For $265M
    Last update: 11/18/2010 12:41:06 AM

    TOKYO (Dow Jones)--Sekisui Chemical Co. (4204.TO) said Thursday it will buy Genzyme Corp.'s (GENZ) diagnostic products business for $265 million in its latest move to expand its medical operations.

    The Tokyo-based chemical product maker and home builder said it will buy Genzyme's business with 575 employees in North America, the U.K. and Germany by the end of December.

    The diagnostics division of the U.S. pharmaceutical company, most known for its orphan drugs, posted $167 million in sales in 2009. Sekisui and Genzyme have been cooperating in diagnostic product operations since 1995.

    Genzyme is in the midst of fighting a $18.5 billion hostile takeover offer from Sanofi-Aventis S.A., claiming the proposal "dramatically undervalues" the Massachusetts-based drug maker.

    -By Kazuhiro Shimamura, Dow Jones Newswires; 813-6269-2790; kazuhiro.shimamura@dowjones.com (END)

    Dow Jones Newswires

    November 18, 2010 00:41 ET (05:41 GMT)

    DRW
  5. flosz 18 november 2010 18:01
    Sanofi/Shantha vax fix will require WHO requalification
    November 17, 2010 — 11:28am ET | By George Miller

    Sanofi-Aventis ($SNY) expects its Shantha SHAN5 VACCINE FOR FIVE CHILDHOOD DISEASES TO BE OFF THE MARKET UNTIL 2013 while it rebounds from manufacturing issues that yielded white sediment in some vials. The sediment was enough for the World Health Organization to cancel its Unicef order with the drug giant through 2012.
    Bloomberg reports that Sanofi has provided the WHO with a corrective action plan. BUT THE EXTENT OF THE MEASURES TO BE TAKEN REQUIRES THE COMPANY TO REAPPLY FOR PREQUALIFICATION. The vaccine with sediment was manufactured before Sanofi bought Shantha in 2009

    MEANWHILE, THE WHO HAS TRACED THE SEDIMENT TO SHAN5'S WHOOPING-COUGH COMPONENT AND, IN DOMINO FASHION, THE GLOBAL HEALTH AUTHORITY HAS SUSPENDED THE PREQUALIFICATION OF A SHANTHA FOUR-IN-ONE VACCINE THAT INCLUDES THE SAME COMPONENT AND HALTED THE APPROVAL PROCESS FOR A THREE-IN-ONE SHOT.
    Sanofi mentioned when it acquired Shantha in 2009 that the Indian drugmaker's manufacturing facilities provided the drug giant with high-quality capacity for making affordable vaccines available globally. Likewise, Johnson & Johnson ($JNJ) last month heralded excellence in manufacturing and supply chain in announcing its acquisition of vaccine maker Crucell. That announcement was quickly followed by Crucell suspending operations at a South Korean facility and halting shipments of two products--the pentavalent Quinvaxem and Hepavax-Gene for hepatitis B--due to contamination concerns. CRUCELL SAID IT EXPECTS TO RESUME SHIPPING THIS MONTH AND THAT IT ANTICIPATES FULL AVAILABILITY OF THE VACCINES IN FEBRUARY.

    www.fiercepharmamanufacturing.com/sto...
  9. [verwijderd] 26 november 2010 19:05
    Genzyme Has Tactics To Fend Off Sanofi
    Last update: 11/26/2010 8:35:42 AM

    PARIS -- Genzyme Corp. (GENZ) Chief Executive Henri Termeer said that the company has a list of possible "poison pill" tactics it could employ to fend off advances from French pharmaceutical giant Sanofi-Aventis SA (SAN.FR, SNY) but that it hasn't made any decisions on the issue, according to an interview published in Friday's edition of the French daily Le Figaro.

    The company is also reflecting on how a potential acquirer of the company could provide extra payments linked to the future performance of its Campath drug, which could serve "Sanofi or other companies we're in discussions with," Termeer added, according to the interview.

    He declined to provide any further details about companies the Boston-based biotech is in discussions with. Genzyme's board continues to believe that Sanofi's offer of $69 a share is unacceptable, and there is currently "nothing that would allow us to engage in discussions," Termeer said.

    Newspaper Web site: www.lefigaro.fr

    -By Paris Bureau, Dow Jones Newswires; 33-1-4017 1740 (END)

    Dow Jones Newswires

    November 26, 2010 08:35 ET (13:35 GMT)
  10. [verwijderd] 1 december 2010 15:28
    Malaysia Testing Dengue Vaccine As Deaths Surge
    Last update: 12/1/2010 4:32:07 AM

    KUALA LUMPUR, Malaysia (AFP)--Malaysian health authorities announced Wednesday that they were testing a dengue vaccine in a bid to combat the disease that has seen its death rate in the country jump more than 60% this year.

    There is currently no treatment or vaccine for the mosquito-borne disease, which has killed 128 people this year in Malaysia, compared to 78 deaths in the same period a year ago.

    Malaysian health authorities said they started clinical trials involving some 300 volunteers in the middle of the year, and would carry out further trials from December. "If these studies are successful, we hope the vaccine can be made available to the Malaysian people in the next few years," health ministry director general Ismail Merican said in a statement.

    "A dengue vaccine is the ultimate next step in the prevention of dengue fever," said the top health official, who described the trials as the "latest breakthrough."

    Malaysia is working with Sanofi Pasteur, the vaccines division of French pharmaceutical firm Sanofi-Aventis SA (SAN.FR), to develop the vaccine. Nearly 43,500 dengue fever cases have been reported in Malaysia this year, and the public is being urged to take action to eradicate the Aedes aegypti mosquito--which spreads dengue--from homes and workplaces.

    Malaysia is also planning to conduct a controversial field trial by releasing genetically-modified mosquitoes--the first experiment of its kind in Asia. The virus has historically been found in tropical regions, particularly in urban and semi-urban areas, but has spread in recent years to colder and higher places and is now endemic in more than 100 countries. (END)

    Dow Jones Newswires

    December 01, 2010 04:32 ET (09:32 GMT)
  11. flosz 6 december 2010 12:51
    Sanofi Pasteur withdraws its marketing authorisation application for Emerflu, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

    The European Medicines Agency has been formally notified by Sanofi Pasteur of its decision to withdraw its application for a centralised marketing authorisation for Emerflu, a pandemic influenza vaccine (split virion, inactivated, adjuvanted) A/Vietnam/1194/2004 NIBRG-14, 30 μg of haemagglutinin + aluminium hydroxide adjuvant, suspension for injection.
    This medicine was intended to be used for prophylaxis of influenza in an officially declared pandemic situation. A core pandemic dossier was submitted in the context of prevention of influenza in an officially declared pandemic situation, according to the mock-up vaccine procedure.
    The application for the marketing authorisation for Emerflu was submitted to the Agency on 27 April 2007. Emerflu received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) on 19 March 2009 and at the time of withdrawal a European Commission decision was pending.
    In its official letter, the company stated that its decision to withdraw the application was based on the CHMP’s consideration that the data provided do not allow the Committee to conclude on a positive benefit/risk balance.
    More information about Emerflu and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency’s website after the next CHMP meeting on 13 - 16 December 2010.
    www.ema.europa.eu/docs/en_GB/document...
    Via twitter.com/Dutchy123
  12. [verwijderd] 6 december 2010 13:01
    quote:

    flosz schreef:

    Sanofi Pasteur withdraws its marketing authorisation application for Emerflu, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)

    Opnieuw goed nieuws voor Crucell. Sanofi zal een nieuwe aanpak moeten kiezen. Misschien de met miljarden uitpuilende kas inzetten in de strategische pijplijn van Crucell?
  14. forum rang 10 voda 8 december 2010 17:27
    'Sanofi verlengt bod op Genzyme'
    8 december 2010, 9:44 | ANP
    NEW YORK (AFN) - Het Franse biotechnologieconcern Sanofi-Aventis verlengt de termijn voor zijn overnamebod op de Amerikaanse branchegenoot Genzyme, dat vrijdag afloopt. De Fransen verhogen het bod van 69 dollar per aandeel, ofwel 24,4 miljard dollar (18,5 miljard euro), niet. Dat meldde het dagblad Le Figaro woensdag.

    Genzyme heeft zich van meet af aan verzet tegen de avances van Sanofi en vindt het bod veel te laag. Volgens Genzyme zouden de Fransen tussen 84 en 89 dollar per aandeel moeten bieden. ,,Wij erkennen dat het een serieus bod is, maar het is geen adequaat bod'', zei Genzymetopman Henri Termeer afgelopen vrijdag tijdens een investeerdersbijeenkomst.

  17. [verwijderd] 10 december 2010 12:23
    Laat zijn eerste job maar zijn, een goed bod op Crucell.

    Sanofi: Olivier Charmeil To Head Vaccines Unit
    Last update: 12/10/2010 6:14:07 AM

    PARIS (Dow Jones)--French drugs giant Sanofi-Aventis (SNY) Friday said it has appointed Olivier Charmeil to head its vaccines division, Sanofi Pasteur. Charmeil, who runs the company's Asia Pacific and Japan operations, will replace Wayne Pisano when he retires in February next year. Charmeil will join the group's executive committee.

    -By Mimosa Spencer, Dow Jones Newswires; +33 1 4017 1740; mimosa.spencer@dowjones.com (END) Dow Jones Newswires

    December 10, 2010 06:14 ET (11:14 GMT)
  19. forum rang 10 voda 13 december 2010 13:37
    Sanofi verlengt bod op Genzyme
    13 december 2010, 7:31 | ANP
    PARIJS (AFN) - Het Franse biotechnologiebedrijf Sanofi-Aventis verlengt de termijn voor het overnamebod op zijn Amerikaanse branchegenoot Genzyme tot 21 januari. Dat maakte de onderneming maandag bekend. De condities van het bod wijzigen niet.

    De vorige termijn liep afgelopen vrijdag af. De Fransen verhogen het bod van 69 dollar per aandeel, ofwel 24,4 miljard dollar (18,5 miljard euro), niet. Genzyme heeft zich van meet af aan verzet tegen de avances van Sanofi en vindt het bod veel te laag. Volgens Genzyme zouden de Fransen tussen 84 en 89 dollar per aandeel moeten bieden.

    Sanofi gaf maandag ook aan dat er tot nu toe ruim 2 miljoen aandelen Genzyme zijn aangemeld onder het bod. Dat is circa 0,9 procent van het aandelenkapitaal.

  20. [verwijderd] 13 december 2010 14:52
    0,9 procent in ruim 2 maanden en het bod was inmiddels afgelopen.........hoopt men met de verlenging nog 0,2 procent binnen te halen?.....volstrekt kansloos maar men wil kennelijk tijd winnen om de aandeelhouders wel een succes te kunnen melden

    ....als Sanofi nu eens een paar miljard, van die 20 die men in de oorlogskas heeft, gebruikt om de Crucell technologie en pijplijn op te kopen?
785 Posts
Pagina: «« 1 ... 35 36 37 38 39 40 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 878,83 -0,39%
EUR/USD 1,0675 +0,05%
FTSE 100 8.121,24 -0,28%
Germany40^ 17.905,20 -1,18%
Gold spot 2.304,11 -1,36%
NY-Nasdaq Composite 15.657,82 -2,04%

Stijgers

Corbion
+2,70%
B&S Gr...
+1,20%
Ahold ...
+1,17%
ForFar...
+1,04%
OCI
+1,00%

Dalers

VIVORY...
-13,94%
EBUSCO...
-5,50%
ACOMO
-4,69%
Air Fr...
-4,29%
Arcadis
-3,88%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!